SHLP2
unknown riskAlso: Small Humanin-Like Peptide 2 · SHLP-2 · mt-sRNA SHLP2
SHLP2 is a mitochondria-derived peptide (MDP) encoded in the mitochondrial 16S rRNA gene. It shares structural and functional homology with Humanin and demonstrates insulin-sensitizing and anti-apoptotic activity, with preliminary evidence suggesting relevance to metabolic disease and aging.
Reported Benefits
Insulin Sensitization
In vitro and rodent data show improved insulin signaling in hepatic and skeletal muscle tissue at nanomolar concentrations.
Anti-apoptotic
Protective against apoptosis in neuronal and cardiomyocyte cell lines exposed to oxidative stress and hypoxia.
Mitochondrial Protection
Maintains mitochondrial membrane potential and reduces reactive oxygen species in stressed cell models.
Mechanism of Action
SHLP2 signals through a receptor complex homologous to the Humanin receptor (CNTFR/WSX-1/gp130), activating JAK2/STAT3 and PI3K/AKT pathways. It inhibits pro-apoptotic Bax activity, reduces mitochondrial ROS generation, and enhances IRS-1 phosphorylation in insulin-sensitive tissues. Its mitochondrial origin suggests it functions as a retrograde signal from mitochondria to nucleus under metabolic stress conditions.
Key Clinical Studies
Cobb LJ et al. (2016)
preclinical · Cell culture + rodent models
SHLP2 demonstrates anti-apoptotic and metabolic effects consistent with humanin; circulating levels correlate inversely with insulin resistance in rodent aging models
Overview
SHLP2 (Small Humanin-Like Peptide 2) is one of six SHLP peptides identified in the mitochondrial 16S rRNA open reading frame — a region of the mitochondrial genome previously considered non-coding. Its discovery as part of the MDP (mitochondria-derived peptide) family reflects a broader revision in mitochondrial biology: the organelle is not merely an energy factory but an active signaling node that encodes functional peptides secreted in response to cellular stress.
Among the SHLPs, SHLP2 is most frequently cited for its metabolic effects — specifically insulin sensitization in hepatic and skeletal muscle tissue, and anti-apoptotic protection in neuronal and cardiac cells.
Insulin Sensitization
SHLP2’s insulin-sensitizing activity appears to operate through IRS-1 phosphorylation enhancement — improving downstream insulin receptor signaling without directly binding the insulin receptor. In rodent models of high-fat diet-induced insulin resistance, SHLP2 administration reduces HOMA-IR and improves glucose tolerance. The JAK2/STAT3 axis is implicated, shared with Humanin but with distinct potency characteristics at the same concentration.
Circulating SHLP2 levels in aging rodents inversely correlate with the degree of insulin resistance — a pattern parallel to what is observed with Humanin in aging human cohorts, suggesting a physiological role in metabolic homeostasis that declines with age.
Anti-apoptotic Profile
In cardiomyocytes exposed to ischemia-reperfusion conditions, SHLP2 maintained mitochondrial membrane potential and reduced caspase-3 activation. Neuronal protection against Aβ toxicity and oxidative glutamate toxicity has been demonstrated at nanomolar concentrations in cell culture. The Bax inhibition mechanism is consistent with the broader MDP family anti-apoptotic signature.
Research Context
SHLP2 lacks the research depth of Humanin — fewer independent groups, smaller study counts, and no human biomarker correlations established. Its biological plausibility is high given mechanistic overlap with Humanin, but it is best understood as a preliminary signal warranting deeper investigation rather than an established compound.
✦ Sponsored
Stop Guessing About Your Health. Start Optimizing It.
Advanced diagnostics and licensed medical providers delivering personalized longevity care to uncover root causes, optimize health, and track progress virtually or in person.
Learn More →
Regulatory Status
Research OnlyNot FDA-approved; no 503A listing; research compound
Safety Profile
Side Effects
- •No adverse effects identified in preclinical studies
Contraindications
- •Unknown; no human safety data available
Drug Interactions
- •Theoretical interaction with insulin sensitizers (additive effect, uncharacterized)
Primary Uses
Planning a protocol?
Use the AI Stack Builder to generate a phased schedule, compatibility analysis, and monitoring checklist.
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe SHLP2?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →